The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound
Participants who switched to orforglipron from Wegovy maintained all but ... [28021 chars]